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1. Introduction 
Prostaglandins (PG), generated by cyclooxygenase (COX), are a group of lipid mediators 
formed in response to various stimuli. They include PGD2, PGE2, PGF2alpha, and PGI2. 
Immediately after synthesis, they are released outside the cell and exert their actions by 
binding to a G-protein-coupled rhodopsin-type receptor on the surface of target cells. There 
are seven types of prostaglandin receptors: the PGD receptor, four subtypes of PGE 
receptor, the PGF receptor, and the PGI receptor. Prostaglandins are involved in host 
defense against various pathogens. Along with mediating inflammatory symptoms, PGs 
might suppress some innate immune factors, including nitric oxide (NO) production. These 
immunomodulatory molecules have been shown to participate in the regulation of virus 
replication and the modulation of inflammatory responses following infection. Moreover, 
virus infection also stimulates the expression of a number of proinflammatory gene 
products, including COX-2, inducible nitric oxide synthase (iNOS) as well as 
proinflammatory cytokines. 
An overproduction of PGE2 (as high as 10−4M) is seen in a number of disorders (e.g. allergy, 
hyper-IgE syndrome, Hodgkin lymphoma, trauma, sepsis, and transplantation), most of 
which are characterized by elevated Th2 and IgE responses. Elevated levels of PGE2 have 
also been reported in individuals infected with HIV-1 and it has been postulated that this 
may contribute to the immunosuppressive state seen in such virally infected patients. The 
mechanism(s) responsible for the enhanced prostaglandin formation is still undefined. The 
initial contact between the virus particle and its target cell might represent the crucial step 
leading to the production of PGE2 by macrophages. This concept is supported by the finding 
that a significant production of endogenous PGE2 is induced (20- to 40-fold increase) 
following incubation of primary human monocytes with the HIV-1 external envelope 
glycoprotein gp120. Given that pro-inflammatory molecules such as PGE2 are up-regulated 
during HIV-1 infection, an imbalance in PGJ2 production is observed in HIV+ individuals.   
This book chapter will focus on roles of prostaglandins in HIV-1 replication and their 
potential therapeutic implications. We propose to review mechanisms by which the pro-
inflammatory prostaglandin PGE2 and the anti-inflammatory prostaglandin PGJ2 regulate 
HIV-1 transcription and replication. Specific attention will be placed on how prostaglandins 
affect the nuclear translocation of NF-B (nuclear factor kappa B), an essential transcription 
factor for HIV-1 transcription. In addition, signaling pathways as well as other transcription 
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factors that are activated or repressed by prostaglandins that regulate HIV-1 gene 
expression will be reviewed.  
2. Prostaglandins: Their synthesis and roles in the regulation of inflammation 
2.1 Prostaglandins synthesis 
The initial reaction in prostaglandin production is phospholipase A2 (PLA2)-mediated 
liberation of a 20-carbon essential fatty acid, arachidonic acid, from membrane phospholipids. 
Cyclooxygenase (COX) is the rate-limiting enzymes catalysing oxidation of arachidonic acid to 
the hydroperoxyendoperoxide, prostaglandin G2 (PGG2). Subsequently, PGG2 is reduced to 
form the hydroxylendoperoxide, prostaglandin H2 (PGH2). Then, prostanoids including 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2ǂ), prostacyclin 
(PGI2), and thromboxane A2 (TXA2) are formed by the action of discrete prostaglandins 
synthases (reviewed in Coleman et al., 1994). Figure 1 reviews the arachidonic cascade. 
 
 
Fig. 1. A model for prostaglandins synthesis. 
Prostaglandin E2 (PGE2), an oxygenated polyunsaturated fatty acid that contains a 
cyclopentane ring structure, is present in high concentrations in individuals infected with 
numerous pathogens (Abel et al., 1992; Ben-Hur et al., 1996; Farrell & Kirkpatrick, 1987; 
Foley et al., 1992; Griffin et al., 1994a; Henke et al., 1992; Kernacki & Berk, 1994; Midulla et 
al., 1989; Onta et al., 1993; Ramis et al., 1992; Rastogi et al., 1992; Reiner & Malemud, 1984; 
Sorrell et al., 1989; Wang & Chadee, 1992, 1995). PGE2 are molecules that have been shown 
to modulate the immune response both in vitro and in vivo (Goodwin & Webb, 1980). 
Macrophages, follicular dendritic cells, fibroblasts, and vascular endothelial cells synthesize 
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PGE2, while lymphocytes do not secrete this major product of arachidonic acid metabolism  
(Frey et al., 1986; Heinen et al., 1986; Kurland & Bockman, 1978; Phipps et al., 1988). A 
marked increase in PGE2 production is generated in response to a variety of immunological 
stimuli including interleukin (IL)-1, tumor necrosis factor-ǂ (TNF-ǂ), antigen-antibody 
complexes, and lipopolysaccharide (Roper & Phipps, 1994) in addition to exposition to 
microorganisms. PGE2 has been implicated in decreasing T-cell proliferation, IL-2 
production, and IL-2 receptor expression (Goodwin et al., 1977; Goodwin & Ceuppens, 1983; 
Rincon et al., 1988; Roper & Phipps, 1994; Walker et al., 1983). PGE2 shifts the balance of the 
cellular immune response away from T-helper type 1 (Th1) favouring a Th2 response which 
drives humoral responses toward the production of IgE (Fedyk & Phipps, 1996). However, 
other findings have depicted PGE2 as a pleiotropic molecule that can act both negatively or 
positively on the immune system (Phipps et al., 1991). Depending on the cell type, binding 
of PGE2 to one of its six described receptors (EP1, EP2, EP3I, EP3II, EP3III, and EP4) can lead to 
phospholipase C activation, phosphatidylinositol turnover increase, activation of adenylate 
cyclase through cholera toxin-sensitive Gs proteins and mobilization of intracellular Ca2+ 
concentration (Coleman et al., 1994). PGE2 facilitates expansion of the Th17 subset of T 
helper cells of both human and mouse through elevation of cAMP via PGE2 receptors EP2 
and EP4 (Sakata et al., 2010). 
The balance of opposing prostaglandins produced in tissues profoundly influences 
inflammatory responses (Harris et al., 2002). The J series of prostaglandins are the end 
product metabolites of PGD2 and are abundantly produced by mast cells, platelets, as well 
as alveolar macrophages (Ito et al., 1989; Straus & Glass, 2001). One of these molecules, 15-d-
PGJ2, is a natural activator of the peroxisome proliferators-activated receptor-Ǆ (PPAR-Ǆ), a 
nuclear receptor family member that elicits anti-inflammatory activities in macrophages  
(Hinz et al., 2003; Hortelano et al., 2000; Jiang et al., 1998; Ricote et al., 1998), lymphocytes 
(Clark et al., 2000; Padilla et al., 2000; Yang et al., 2000), dendritic cells (Faveeuw et al., 2000), 
and endothelial cells (Imaizumi et al., 2003). Currently, the mechanisms regulating the anti-
inflammatory effects of 15-d-PGJ2 and other PPAR-Ǆ agonists are poorly understood, but it 
has been suggested to involve the inhibition of the nuclear factor B (NF-B) signaling 
pathway  (Daynes & Jones, 2002; Rossi et al., 2000). PPAR-Ǆ is also expressed at high levels 
both in the colonic epithelium and intestinal epithelial cells (Lefebvre et al., 1998; Saez et al., 
2004; Saez et al., 1998; Sarraf et al., 1998; Sarraf et al., 1999), where, depending on the model 
system studied, it can result in either an increase or a decrease in proliferation (Brockman et 
al., 1998; Lefebvre et al., 1998). 
2.2 Prostaglandins and HIV infection 
An overproduction of PGE2 as high as 10−4M is seen in a number of disorders (e.g.allergy, 
hyper-IgE syndrome, Hodgkin lymphoma, trauma, sepsis, and transplantation), most of 
which are characterized by elevated Th2 and IgE responses (Fedyk & Phipps, 1996; 
Haraguchi et al., 1995a; Phipps et al., 1991; Roper & Phipps, 1994). Elevated levels of PGE2 
have also been reported in individuals infected with HIV-1 (Abel et al., 1992; Foley et al., 
1992; Griffin et al., 1994a; Ramis et al., 1992) and it has been postulated that this may 
contribute to the immunosuppressive state seen in such virally-infected patients (Hui et al., 
1995). In vitro, peripheral blood monocytes and macrophages from AIDS patients exhibit 
abnormal production of cyclooxygenase products (Coffey et al., 1999; Fernandez-Cruz et al., 
1989; Foley et al., 1992; Mastino et al., 1993; Ramis et al., 1991). The mechanism(s) 
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responsible for the enhanced prostaglandin formation is still undefined. The initial contact 
between the virus particle and its target cell might represent the crucial step leading to the 
production of PGE2 by macrophages. Significant production of endogenous PGE2 is induced 
(20- to 40-fold increase) following incubation of primary human monocytes with the HIV-1 
external envelope glycoprotein gp120 (Wahl et al., 1989). However, in sharp contrast with 
this report, a previous study has demonstrated that interaction between gp120 and THP-1, a 
human monocytoid cell line, does not increase exogenous production of PGE2 (Hui et al., 
1995). It is important to specify that, unlike monocyte/macrophages, promonocytoid THP-1 
cells are not at a terminal stage of differentiation. In addition, a monomer form of gp120 was 
used in this study which might not parallel physiological conditions where gp120 is under a 
multimeric form (Pinter et al., 1989). 
3. PGE2 and HIV transcription 
3.1 Importance of NF-B in HIV-1 gene transcription 
HIV-1 gene expression is regulated in a cell type- and differentiation-dependent manner by the 
binding of both host and viral proteins to the long terminal repeat (LTR), which serves as the 
viral promoter. Host transcription factors such as the Sp family, NF-B family, activator 
protein 1 (AP-1) proteins, nuclear factor of activated T cells (NFAT), and CCAAT enhancer 
binding protein (C/EBP) family members play essential roles in the regulation of HIV-1 
transcription by binding sites in the LTR that display different levels of sequence conservation 
(Fig 2). Viral proteins such as HIV Vpr and Tat also bind to the LTR to regulate transcription 
(Kilareski et al., 2009). Many of these host and viral proteins engage in extensive protein-
protein interactions, leading to a complex system of transcriptional regulation. 
 
 
Fig. 2. A schematic representation of a typical HIV-1 LTR. 
The transcription factor NF-B is known to play a central role in the activation of HIV-1 
gene expression. The enhancer in the U3 region of LTR contains two NF-B binding sites 
(Siebenlist et al., 1994) that are critical for LTR promoter activity and important for optimal 
HIV-1 replication (Santoro et al., 2003; Siebenlist et al., 1994). NF-B is an inducible 
transcription factor that plays an important role in cellular gene expression associated with 
immune responses, inflammation and cell survival (Ghosh et al., 1998; Viatour et al., 2005). 
In the host cytoplasm, NF-B is a heterodimeric molecule (p50/p65) that forms an inactive 
complex with its inhibitor IB. Stimulation with inflammatory cytokines, such as TNF-ǂ and 
IL-1ǃ, viral and bacterial antigens, and stress-inducing agents leads to immediate 
phosphorylation and subsequent degradation of IB by the proteasome, resulting in the 
translocation of NF-B from the cytoplasm to nucleus. 
3.2 Activation of HIV-1 LTR activity by PGE2 
Immune and inflammatory responses are triggered by microorganisms such as bacteria, 
viruses, and protozoan, all known to be potential opportunistic pathogens in HIV-1-positive 
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patients. The formation and production of elevated levels of inflammatory mediators such 
as PGE2 is a hallmark of the HIV-1 infection (Foley et al., 1992; Griffin et al., 1994a; Ramis et 
al., 1992). Prostaglandins play a role in disease exacerbation by directly altering T-cell 
functions or macrophage activation. Although it was thought that PGE2 is primarily an 
immunosuppressive molecule that acts as a down-regulator of many aspects of B- and T-cell 
function and proliferation, other findings support a role for PGE2 as a potentiator of 
immunoglobulin class switching and cytokines and cytokine receptors synthesis (Phipps et 
al., 1991). Moreover, knowing that PGE2 is a good inducer of cAMP and that a 4-fold 
increase in intracellular levels of cAMP is seen in asymptomatic HIV-1-seropositive subjects 
as compared with uninfected controls (Hofmann et al., 1993), it is thus of prime importance 
to study the putative effect of PGE2 on the regulatory elements of HIV-1 in T cells 
considered to be the major cellular reservoir for HIV-1 in the human peripheral blood. As 
shown in Fig 3, exogenous PGE2 could further increase the overall positive effect mediated 
by various HIV-1 LTR-activating agents confirming that PGE2 could be considered by itself 
as a potent inducer of HIV-1 LTR transcription in T cells. 
 
 
Fig. 3. Activation of HIV-1 LTR by several stimuli in the absence or presence of PGE2. 1G5 
cells, a clonal cell line derived from Jurkat E6.1 cells which has been with stably transfected 
with a luciferase gene driven by the HIV-1 LTR (Aguilar-Cordova et al., 1994), were either 
left untreated (control) or treated with PHA (3 μg/ml), OKT3 (1 μg/ml), PMA (20 ng/ml), 
or TNF-ǂ (2 ng/ml) in the absence or presence of 100 nM PGE2 for 8 h. Cell lysates were 
evaluated for luciferase activity and are expressed as fold induction relative to basal 
luciferase activity in untreated control cells (considered as 1). 
Northern blot assays, flow cytometric analyses, and pharmacological studies showed that 
the EP4 gene is expressed on T lymphoid cells such as Molt-4, KM-3, IG5 and Jurkat E6.1 
(Blaschke et al., 1996; De Vries et al., 1995; Dumais et al., 1998; Mori et al., 1996). It has been 
demonstrated that EP4 receptors are coupled to adenylate cyclase via a stimulatory G 
protein (Gs) and that such activation results in an enhancement of intracellular cAMP levels 
(Coleman et al., 1995; Nishigaki et al., 1995). Interestingly, PGE2 has been shown to lead to 
an increase in intracellular cAMP levels partly via the EP4 receptor (Rodbell, 1980), a finding 
which lend credence to the potential implication of the EP4 receptor in the PGE2-induced up-
regulation of HIV-1 LTR activity. 
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3.2.1 NF-κB-dependent signaling pathways involved in activation of HIV-1 LTR by 
PGE2 in T cells 
The involvement of specific intracellular second messengers in PGE2-mediated up-
regulation of HIV-1 LTR activity has been dissected using several signal transduction 
inhibitors. Only exogeneous PGE2 plays a role in the activation of HIV-1 LTR-driven gene 
expression as shown with experiments using indomethacin, a potent inhibitor of the 
cyclooxygenase pathway (Dumais et al., 1998). Moreover, it was demonstrated that T cells 
had a limited capacity to metabolize arachidonic acid to prostaglandins (Auberger et al., 
1989; Fu et al., 1990; Goldyne & Rea, 1987). Interaction between PGE2 and an adenylate 
cyclase-coupled stimulatory receptor leads to activation of adenylate cyclase, hydrolysis of 
ATP, enhanced turnover of intracellular cAMP and binding to PKA (Kammer, 1988). In T 
cells, PGE2-induced enhancement of HIV-1 LTR dependent activity requires the 
participation of adenylate cyclase, cAMP as well as protein kinase A (Dumais et al., 1998) 
and elevation of cAMP levels resulted in HIV-1 replication (Nokta & Pollard, 1992). It is also 
well known that cAMP-dependent pathways regulate the immune effector functions of 
lymphocytes and macrophages. For example, during immune response, cAMP exhibits 
positive regulatory effects at low concentrations whereas inhibitory effects are seen at high 
concentrations (Koh et al., 1995). Many of the earlier studies have shown that PGE2 
interaction with T cells in vitro resulted in an elevation of the cAMP level (Rincon et al., 
1988) and that such elevated intracellular cAMP levels were responsible for the proliferative 
disturbances in T cells (Baker et al., 1981; Lingk et al., 1990; Munoz et al., 1990). In T cells, 
experiments with the calcium chelator BAPTA/AM and the calcium inhibitor CAI are 
suggestive of the importance of Ca2+ in the PGE2-induced activation of HIV-1 transcription 
(Dumais et al., 1998). However, given that there is no published report indicating Ca2+ influx 
through the EP4 receptor, our results with BAPTA/AM and carboxyamido-triazole (CAI), 
two inhibitors of intracellular calcium mobilization, lead us to postulate that PGE2 could 
generate calcium release from intracellular storage organelles.  Up-regulation of HIV-1 LTR 
requires the implication of cAMP and calcium, as well as the participation of the NF-B 
transcription factor. 
Several agents known as potent activators of HIV-1 transcription (e.g. PMA, PHA, TNF-ǂ, 
and anti-CD3 antibody) are all acting through a common mechanism, namely via the 
nuclear translocation of the transcription factor NF-B which binds to the enhancer region of 
the HIV-1 LTR (Nabel, 1991). This transcription factor is sequestered in the cytoplasm due to 
its physical association with the inhibitor named IB. NF-B is a pleiotropic transcription 
factor that controls the expression of a wide variety of genes, including cytokines such as IL-
1, IL-2, IL-6, IL-8, interferon-ǃ, and TNF-ǂ, as well as known genes for some cell adhesion 
molecules including ICAM-1 and VCAM-1. Its importance in the regulation of HIV-1 gene 
expression has been stated in numerous studies (Siebenlist et al., 1994). Results from 
mobility shift assays suggest that the PGE2-mediated effect on HIV-1 LTR activity is due to 
activation of the transcription factor NF-B. This is in agreement with the previous 
demonstration that PGE2 activates NF-B in the macrophage-like cell line J774 (Muroi & 
Suzuki, 1993). The fact that we have noticed that both NF-B and Ca2+ are key elements in 
the PGE2 effect on HIV-1 transcription is of interest considering that calcineurin, a 
Ca2+/calmodulin-dependent serine/threonine protein phosphatase, has been reported to 
activate NFB through the inactivation of IB (Frantz et al., 1994). Moreover, researchers 
had earlier found that cAMP-mediated enhancement of PKA might be involved in the 
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dissociation of IB from NF-B (Nabel and Baltimore, 1987). Recent studies have revealed 
that NF-B is regulated through phosphorylation of the p65 subunit by PKA which is 
directly regulated by intracellular levels of cAMP (Zhong et al., 1997). Experiments in Jurkat 
E6.1 T cells performed with B-driven reporter gene constructs (pB-TATA-LUC and pNF-
B-LUC) and HIV-1 LTR-based vectors (pLTR-LUC and pmBLTR-LUC), suggest that NF-
B-binding regions and another element(s) in the HIV-1 LTR are involved in the activation 
of HIV-1 LTR-dependent transcription induced by PGE2 (fig 4). These results hence support 
the notion that PGE2 might be activating the transcription factor NF-B via cAMP/PKA and 
calcium signaling pathways in human T lymphoid cells. 
 
 
Fig. 4. NF-B-dependent and -independent activation of HIV-1 LTR by PGE2. Jurkat E6.1 
cells were transiently transfected with pLTR-LUC, pmBLTR-LUC, pNF-B-LUC or pB-
TATA-LUC and were either left untreated or were treated for 8 h with TNF-ǂ (2 ng/ml), 
PHA/PMA (3 μg/ml and 20 ng/ml, respectively), or PGE2 (100 nM). Results shown are 
expressed as fold induction relative to basal luciferase activity in untreated control cells 
(considered as 1). 
3.2.2 Other transcription factors implicated in the PGE2-induced HIV-1 gene 
transcription 
PGE2 could have the capacity to modulate several signal transduction pathways through its 
effect on transcription factors regulated by cAMP such as the cAMP response-element 
binding factor, the activating protein-1 (Haraguchi et al., 1995b) and Sp1 (Rohlff et al., 1997). 
The involvement of these three transcription factors in the observed NF-B-independent 
activation of HIV-1 LTR mediated by PGE2 was further investigated. We have previously 
discussed that interaction of PGE2 with EP4 receptor subtype in human T cells can up-
regulate HIV-1 replication via both NF-B-dependent and –independent pathways (Dumais 
et al., 1998). In this section, we will address the functional role played by other transcription 
factors in the PGE2-induced HIV-1 LTR activation. 
Several signal transduction pathways have been shown to regulate the expression of 
target genes by inducing the phosphorylation of specific transcription factors (Hunter & 
Karin, 1992). The second messenger cAMP mediates the transcriptional induction of 
numerous genes through protein kinase A (PKA)-dependent phosphorylation of the 
CREB at Ser133 (Gonzalez et al., 1989). CREB is a stimulus-induced 43-kDa basic leucine 
zipper (b-ZIP) transcription factor that binds to an octanucleotide cAMP-responsive 
element (CRE) (i.e., TGANNTCA) both as a homodimer and as a heterodimer in 
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conjunction with other members of the activation transcription factor (ATF)/CREB 
superfamily of transcription factors (Gonzalez & Montminy, 1989; Habener, 1990; Hoeffler 
et al., 1988). It is now believed that the transcriptional regulation of genes containing 
either CCAAT/enhancer binding protein (C/EBP) or ATF/CREB recognition sites may 
involve the heterodimerization between different members of the b-ZIP family. This is 
clearly illustrated by the demonstration that transcription of HIV-1 in monocytic cells is 
regulated by a synergistic interaction between ATF/CREB and C/EBP protein families 
(Ross et al., 2001). The C/EBP-related family of nuclear transcription factors constitutes a 
class of proteins characterized by their ability to bind the CCAAT consensus sequence, 
inducing either transcriptional activation or repression of target genes (Cao et al., 1991; 
Chodosh et al., 1988; Johnson & McKnight, 1989; Williams et al., 1991). Members of this 
family include C/EBPǂ, C/EBPǃ (also termed LAP, NF-IL6ǂ, IL-6DBP, AGP/EBP), 
C/EBPǄ, C/EBPǅ (NF-IL6) and C/EBPǆ (Mueller et al., 1990). Interestingly, regulatory 
sequences of HIV-1, which are located within the LTR, harbor three C/EBP sites that bind 
C/EBPǃ (Tesmer et al., 1993) (Fig 2) and these sites are essential to initiate virus 
replication in cells of the monocyte/macrophage lineage (Henderson et al., 1995) and in 
endothelial cells as recently described (Lee et al., 2001). PKA and transcription factors of 
the ATF/CREB family may be critical for HIV-1 expression and regulation. In this regard, 
HIV-1 infection has been associated with sustained elevation of cAMP in T cell lines and 
in normal peripheral blood mononuclear lymphocytes (Nokta & Pollard, 1992). Moreover, 
HIV-1 replication has been shown to be modulated by intracellular levels of cAMP 
(Dumais et al., 1998; Nokta & Pollard, 1992). For example, activation of the cAMP/PKA 
pathway by cholera toxin enhances HIV-1 transcription in latently infected monocytoid 
U1 cells (Chowdhury et al., 1993). It is still unknown whether the HIV-1 genome, 
especially the LTR, possesses CRE sequences. However, the downstream sequence 
elements located in the U5 domain of HIV-1 LTR has been proposed to act as 12-O-
tetradecanoylphorbol-13-acetate/phorbol ester responsive element (TRE)-like CRE that 
bind both AP-1 and CREB/ATF, allowing the induction of HIV-1 LTR activity through 
both protein kinase C and PKA activation signals (Rabbi et al., 1998). 
PGE2 can act as a potent activator of HIV-1 LTR-driven transcription through effects on both 
NF-κB-dependent and -independent signaling events (Dumais et al., 1998). More recently, 
calcium and the CREB transcription factor were also found to be essential second 
messengers in the PGE2-mediated up-regulation of LTR activity in T cells (our unpublished 
observation). Although the binding of a member of the CREB family to the HIV-1 LTR via 
the CRE consensus sequence has not yet been described, it has been postulated that CREB 
can act indirectly on the regulatory elements of this retrovirus. For example, it has been 
shown that CREB interacts with HIV-1 LTR through an association with transcription 
factors such as TFIID and TFIIB (Ferreri et al., 1994; Rohr et al., 1999; Xing et al., 1995) or 
with the adapter CBP; the latter is known to interact with the general transcription 
machinery (Nordheim, 1994). Recently, a recognition sequence for members of the 
ATF/CREB family was identified within the untranslated leader region of HIV-1 as a novel 
TRE-like CRE capable of binding both AP-1 and ATF/CREB (Rabbi et al., 1997). However, 
the U5 region of the HIV-1 LTR is absent from our molecular constructs, rejecting the 
possible implication of TRE-like CRE in the noticed PGE2-induced viral activation. A recent 
report has shown that dopamine treatment of HIV-1-infected T cells leads to the binding of 
CREB to the COUP-TF sequence that is located at the 5' end of the HIV-1 LTR in a region 
called the NRE (Rohr et al., 1999). The various LTR constructs used in our study do not bear 
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the NRE, suggesting that the COUP-TF binding domain is not participating in PGE2-
mediated effect. 
The C/EBP family of nuclear proteins is a member of a larger superfamily of transcription 
factors characterized by the b-ZIP motif that also includes the ATF/CREB family (Johnson, 
1993). In a number of cell types, C/EBPǃ has been shown to function as a cAMP-activated 
transcription factor (Metz & Ziff, 1991; Roesler et al., 1988; Tae et al., 1995). Treatment of 
Jurkat cells with PGE2 resulted in a noticeable induction of nuclear translocation and 
activation of C/EBPǃ. Indeed, DNA mobility shift assays provided clear evidence that PGE2 
and forskolin treatment of human T cells increases the level of specific protein-DNA 
complexes when the consensus C/EBP binding site is used as a molecular probe. Although 
treatment of Jurkat cells with PGE2 did not alter the protein level of C/EBPǃ in whole cell 
extracts, there was a redistribution of this protein from the cytoplasm to the nucleus upon 
exposure to PGE2 (Dumais et al., 2002). 
It has been previously demonstrated that individual C/EBP proteins can homodimerize 
or heterodimerize with other members of the C/EBP family of b-ZIP domain proteins to 
elicit specific cAMP-mediated transcriptional stimulation or repression (Metz & Ziff, 1991; 
Vinson et al., 1989; Williams et al., 1991). Moreover, it is now believed that transcriptional 
regulation of genes containing the recognition sites of either C/EBP or ATF/CREB may 
result from heterodimeric formation between different members in each of the C/EBP and 
ATF/CREB families (Vallejo, 1994). This mechanism may be used to respond to complex 
signals and transcriptional cues through single sequence elements including a response to 
cAMP, despite the absence of active CRE, AP1, and AP2 consensus nucleotide sequences 
(Kagawa & Waterman, 1990; Lund et al., 1990; Pittman et al., 1995). The best example is 
provided by the CFTR gene promoter that is controlled by interactions between C/EBP 
and ATF/CREB family members with CREB1 and ATF1 binding to the inverted CCAAT 
element of this gene to finely regulate its transcription (Pittman et al., 1995). Although the 
absence of CRE certainly may not preclude ATF or CREB protein from targeting 
promoters devoid of such cis-acting elements, it is interesting to note that regulation of 
the somatostatin gene requires protein-protein interaction between C/EBP and 
ATF/CREB transcription factors to elicit a cAMP-dependent response through the CRE 
element (Vallejo, 1994). Inversely, C/EBP proteins have been shown to bind specifically to 
the phosphoenolpyruvate carboxykinase gene CRE with high affinity to promote cAMP-
mediated transcriptional activation (Park et al., 1993). In addition, previous studies 
identified C/EBP as an effector of cAMP-mediated transcription of the 
phosphoenolpyruvate carboxykinase gene through combined interactions with liver-
specific transcription factors (Roesler, 2000; Roesler et al., 1995). Experiments conducted 
with a vector coding for LIP suggested that C/EBP was playing a crucial role in activation 
of HIV-1 LTR-driven gene expression that is seen following treatment of human T cells 
with PGE2 (Dumais et al., 2002). It should be noted that the ǃ-isoform of C/EBP has been 
intimately linked with the cAMP signaling system, as exemplified by the reported 
capacity of cAMP to stimulate C/EBPǃ gene expression (Park et al., 1993) and 
translocation of C/EBPǃ from the cytosol to the nucleus (1991). Thus, we propose that the 
PGE2-dependent increase in HIV-1 LTR transcriptional activity is mediated in part by 
C/EBPǃ. The dominant negative form of C/EBP, i.e., LIP, has less impact on PGE2-
mediated induction of HIV-1 LTR-driven activity than mutating the C/EBP binding sites, 
suggesting that factors in addition to C/EBP may be binding to C/EBP sites. 
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We have identified C/EBP as a PGE2-activated transcriptional regulator of HIV-1 LTR in 
Jurkat cells and demonstrated that C/EBP binding sites are functionally important for virus 
transcription. We also suggest that functional and physical association between members of 
two important transcription factor families, i.e., C/EBP and CREB, are required for 
activation of HIV-1 transcription by PGE2 (Dumais et al., 2002). Our findings represent a 
further indication of the high complexity of the molecular mechanisms that regulate HIV-1 
gene expression following treatment of human T cells with PGE2. Fig 5 reviews the effect of 
PGE2 on HIV-1 LTR transcription. 
 
 
Fig. 5. A model of PGE2-induced HIV-1 LTR activation in T cells. 
3.2.3 Significance 
Results from several studies showed that PGE2 have a major impact in HIV-1 pathogenesis 
exacerbation. Knowing that HIV-infected individuals have a deficiency in the production of 
anti-inflammatory molecules, more knowledge are required to fully understand the 
potential benefit of the resolution of inflammation for people on HAART. Because they are 
clinically important molecules, a further understanding of the roles that prostaglandins 
played in host defense and HIV pathogenesis will have great impact on therapeutic 
research. Detailed characterization of prostaglandins interactions with cells infected with 
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HIV-1 will help us to understand their mechanism of action and establish their therapeutic 
potential in the resolution of inflammation in HIV+ individuals. 
3.3 15-d-PGJ2 and HIV-1 replication/production in intestinal epithelial cells 
Sexual transmission is the predominant mode for epidemic spread of HIV-1 infection 
worldwide. Because semen contains both free HIV-1 virions and HIV-1-infected cells 
(Bouhlal et al., 2002; Royce et al., 1997; Shepard et al., 2000), it can lead to both free and cell-
associated viral transmission. The intestinal mucosa of the rectum, which serves as a site for 
virus entry, is known to play a fundamental role in early HIV-1 infection (Belyakov & 
Berzofsky, 2004; Kozlowski & Neutra, 2003; Neutra et al., 1996). In contrast, the mechanism 
of HIV-1 transmission across the epithelium is not well understood. While it is known that 
the penetration of HIV-1 may occur through lesions in the epithelium (Dickerson et al., 1996; 
Kozak et al., 1997), the existence of lesions is not required (Miller et al., 1990; Spira et al., 
1996). Some studies suggest that HIV-1 can be carried to lymphocytes by dendritic cells 
(Geijtenbeek et al., 2000; Pohlmann et al., 2001). It has been proposed that HIV-1 can cross 
the epithelium barrier via epithelial cell infection. A quantitative analysis of enhanced green 
fluorescent protein-tagged HIV infection of cells derived from the female reproductive tract, 
brain and colon demonstrated that gp120-independent HIV infection occurs in intestinal 
epithelial cells (Zheng et al., 2006). These results clearly illustrate the importance of such 
cells in viral latency and transmission during mucosal HIV-1 infection. Earlier in vitro 
studies showed that HIV can infect human intestinal cell lines lacking CD4 (Fantini et al., 
1991; Fantini et al., 1993). These studies also demonstrated that galactosylceramide (GalCer), 
which binds with high-affinity to gp120, can act as a CD4 surrogate HIV-1 receptor (Meng et 
al., 2002). In fact, Caco-2 cells, a human intestinal cell line, can be infected by HIV-1 via 
GalCer and CXCR4, one of the two known HIV chemokine coreceptors (Delezay et al., 1997; 
Fantini et al., 1993). Also, primary human intestinal cells are capable of selectively 
transferring R5 HIV-1 to CCR5+ cells (cells that express both GalCer and CCR5 on their cell 
surface) (Meng et al., 2002). Thus, they proposed that infection of epithelial cells might 
facilitate HIV-1 penetration into the epithelium barrier (Zheng et al., 2006). Following viral 
replication in the infected epithelial cells, newly formed HIV virions may be discharged into 
the basolateral side of the epithelium and exposed to immune cells present in the mucosal 
milieu. This process may ultimately lead to the dissemination of the virus throughout the 
body. Therefore, it is essential to understand the mechanisms by which HIV replication in 
epithelial cells can be modulated by the immune system molecules present in the mucosal 
milieu. Prostaglandins play key roles in inflammation. During the time course of 
inflammation, the prostaglandins profile shifts from the predominantly pro-inflammatory 
PGE2 to the anti-inflammatory PGJ2, which is the end product metabolite of PGD2 (Gilroy et 
al., 1999; Ianaro et al., 2001; Kapoor et al., 2005a; Kapoor et al., 2005b). Pro-inflammatory 
molecules such as PGE2 are up-regulated during HIV-1 infection (Griffin et al., 1994b; Ramis 
et al., 1991) leading to an imbalance in PGJ2 production. Given that the cyclopentone 
prostaglandin PGJ2 has potent anti-inflammatory properties, it is important to determine 
whether the addition of PGJ2 could inhibit HIV-1 transcription in intestinal epithelial cells.  
Cyclopentone prostaglandins such as PGA1 possess potent antiviral activity against a wide 
variety of viruses such as herpesviruses (Hughes-Fulford et al., 1992; Yamamoto et al., 1987), 
poxviruses (Santoro et al., 1982), paramyxoviruses (Amici et al., 1992; Santoro et al., 1980), 
orthomyxoviruses (Santoro et al., 1988), picornaviruses (Ankel et al., 1985), togaviruses 
www.intechopen.com
  
HIV and AIDS – Updates on Biology, Immunology, Epidemiology and Treatment Strategies 
 
356 
(Mastromarino et al., 1993), rhabdoviruses (Ankel et al., 1985; Santoro et al., 1983) and 
retroviruses (Hayes et al., 2002; Rozera et al., 1996; Skolnik et al., 2002). In macrophages, 
rosiglitazone, troglitazone, and PGJ2 as well as fenofibrate (a PPAR-ǂ agonist) can inhibit 
HIV-1 replication in U1 cells (Skolnik et al., 2002), while PGA1 and PGA2 can inhibit HIV-1 
replication in U937 cells and human monocyte-derived macrophages (Hayes et al., 2002). 
During acute HIV-1 infection in the well-characterized T cell line CEM-SS, treatment with 
cyclopentone prostaglandins such as PGA1 and PGJ2 profoundly alters viral replication 
(Rozera et al., 1996). Moreover, this antiviral effect does not seem to be mediated by 
alterations in the expression of ǂ-, ǃ-, or Ǆ-interferon, TNF-ǂ, TNF-ǃ, IL-6 or IL-10 in HIV-
infected CEM-SS but rather by a direct, as yet unidentified, mechanism (Rozera et al., 1996). 
3.3.1 15-d-PGJ2 inhibition of HIV-1 transcription and viral production 
The potent anti-inflammatory molecule 15-d-PGJ2 strongly suppresses HIV-1 replication and 
particle production in Caco-2 cells, a human intestinal cell line that mimics rectal epithelium 
susceptible to HIV-1 (Delezay et al., 1997; Fantini et al., 1991; Fantini et al., 1992; Fantini et 
al., 1993; Zheng et al., 2006). Prophylactic or co-treatment with 15-d-PGJ2 of intestinal 
epithelial cells significantly reduces HIV replication as well as p24 core antigen production 
(Boisvert et al., 2008). The 15-d-PGJ2-mediated suppression of HIV-1 replication is a result of 
the inhibition of promoter activity as shown by the utilization of a pLTR-luc reporter 
plasmid (Fig 6). This suppression of HIV-1 LTR activity is dose-dependant and is optimal 
24h post-treatment. Moreover, 15-d-PGJ2 inhibition of sodium butyrate (NaBut)-induced 
LTR activity is not specific to Caco-2 cells but can be observed in other intestinal epithelial 
cell lines such as HT-29 and SW620. Sodium butyrate plays major roles in HIV infection. 
Indeed, urinary butyrate levels were increased in the AIDS patients with weight loss 
(2.83±0.67 μmol/l) relative to the controls (1.31±0.13 μmol/l, P<0.05), with the HIV+ patients 
(1.65±0.18 μmol/l) and AIDS patients without weight loss (1.90±0.22 μmol/l) falling in 
between (Stein et al., 1997). NaBut is a deacetylase inhibitor that has been shown to activate 
HIV-1 replication in cells of T-lymphoid and monocytoid origin (Golub et al., 1991). Thus, 
15-d-PGJ2, without significantly changing cell viability or the cell cycle by blocking them in 
G1 phase or altering apoptosis, profoundly affects HIV-1 replication and gene expression in 
intestinal epithelial cell lines (Boisvert et al., 2008). 
 
 
Fig. 6. 15-d-PGJ2-mediated negative effect on HIV-1 LTR activity. Caco-2, SW620 and HT-29 
cells were transiently transfected with pLTR-luc and treated with 15-d- PGJ2 (20 M) used in 
combination with 2 mM NaBut in a 24 h incubation period. Results shown are expressed as 
fold induction relative to basal luciferase activity in untreated control cells (considered as 1).  
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3.3.2 15-d-PGJ2-inhibition of HIV-1 LTR activation is linked to modification to NF-kB 
signaling pathway 
It has been shown previously that 15-d-PGJ2 exerts its effect(s) on cells by activating the PPAR-
Ǆ transcription factor via PPAR-Ǆ, the natural ligand of PGJ2 (Schoonjans et al., 1996; 
Spiegelman, 1998). However, several studies have reported PPAR-Ǆ independent effects of 
PGJ2 on transcriptional regulation via the modulation of NF-B (Rossi et al., 2000; Straus et al., 
2000). In Caco-2, ciglitazone, a PPAR-Ǆ agonist, failed to mimic the PGJ2-induced suppression 
of LTR activity, a result that suggests a PPAR-Ǆ-independent mechanism, such as the NF-B 
pathway, may play a role in this effect in intestinal epithelial cells (Boisvert et al., 2008). This 
result is in contrast to those of Skolnik et al. in 2002 (Skolnik et al., 2002) that showed that 
ciglitazone was able to reduce the HIV-1 promoter activity in monocytes and in peripheral 
blood mononuclear cells (PBMCs). In contrast, ciglitazone induces luciferase activity in this 
experimental model. The induction of NF-B activity in colon cancer cells via p65 
phosphorylation has been previously reported (Chen & Harrison, 2005), and this phenomenon 
may explain why we observed an increase in luciferase expression following the ciglitazone 
treatment of Caco-2 cells. The blockade of PPAR-Ǆ receptor activation by using a specific 
human PPAR-Ǆ antagonist (GW9662) confirms that 15-d-PGJ2 repress LTR activity by a 
mechanism independent of PPAR-Ǆ (Boisvert et al., 2008). Similarly, expression of IL-1ǃ in 
human chondrocytes is inhibited by 15-d-PGJ2 by a PPAR-Ǆ-independent mechanism (Boyault 
et al., 2001) as well as IL-8 expression in endothelial cells (Jozkowicz et al., 2001). 
The PPAR-Ǆ-independent mechanism by which 15-d-PGJ2 mediates its anti-inflammatory 
effect can be dependent upon the inhibition of the NF-B signaling pathway (Daynes & 
Jones, 2002; Rossi et al., 2000). The NF-B binding sites within the HIV-1 promoter confer a 
high level of viral transcription in many cell types (Rabson & Lin, 2000). Previous studies 
have shown that cyclopentone prostaglandins via their ability to modulate NF-B activity, 
significantly alter HIV-1 replication in T cells, monocytes/macrophages and intestinal 
epithelial cells (Boisvert et al., 2008; Hayes et al., 2002; Rozera et al., 1996; Skolnik et al., 
2002). In Caco-2 cells, the functional role of NF-B was determined using pΒ-TATA-luc or 
pNFB-luc expression plasmids (Fig 7). The results demonstrated that the NaBut-induced 
 
 
Fig. 7. NF-B-dependent inhibition of HIV-1 LTR by 15-d-PGJ2. Caco-2 cells were transiently 
transfected with pB-TATA-luc, pmB-luc and pNF-B-luc. Then, cells were treated with  
20 M 15-d-PGJ2 used in combination with 2 mM NaBut in a 24 h incubation period. Caco-2 
cells were lysed and luciferase activity was monitored. Results shown are expressed as fold 
induction relative to basal luciferase activity in untreated control cells (considered as 1). 
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luciferase activity of the pΒ-TATA-luc construct, which contains the HIV-1 enhancer, is 
abrogated by 15-d-PGJ2 in a dose-dependent manner. A control construct containing the 
HIV-1 enhancer with inactivated NF-B binding sites, pmB-luc, was used to show that NF-
B is necessary for the NaBut activation of the HIV-1 LTR in Caco-2. Similar results to pΒ-
TATA-luc were found using the pNFB-luc construct, which contains five consensus NF-κB 
binding sites. Together, these data suggest that NF-B is involved in the 15-d-PGJ2-mediated 
suppression of HIV-1 LTR activation in Caco-2 cells. 
15-d-PGJ2 alters the stability of IBǂ proteins thereby altering NF-κB activation. Moreover in 
human bronchial epithelium, cyclopentone prostaglandin such has PGA1, has been shown to 
enhance the expression of IBǂ, a primary inhibitor of the pro-inflammatory transcription 
factor NF-B (Thomas et al., 1998). In intestinal epithelial cells, IKK activity was lower in Caco-
2 cells treated with 15-d-PGJ2 and the inhibition of IKK activity was direct without increasing 
IBǂ mRNA expression. Another group (Scher & Pillinger, 2005) reported an inhibitory effect 
of 15-d-PGJ2 on NF-B activation and expression of pro-inflammatory genes such as COX-2, 
IL-1ǃ and TNF-ǂ. Interestingly in human chondrocytes, 15d-PGJ2, but not troglitazone, 
modulates IL-1ǃ expression by inhibiting NF-B and AP-1 activation pathways, a mechanism 
independent of PPAR-Ǆ as observed with 15-d-PGJ2 and NaBut-induced LTR activation. 
Moreover, it was shown by electrophoretic mobility shift assays that 15-d-PGJ2 represses the 
nuclear translocation of the ubiquitous transcription factor NF-B, which also results in the 
repression of HIV-1 transcription (Boisvert et al., 2008). Taken together results showed that the 
cyclopentone PGJ2 inhibits NaBut-induced NF-B binding activity in Caco-2 cells. This effect is 
caused by a reduction in the activity of IKK which results in reduced NF-B nuclear 
translocation but not alterations in IκBǂ gene expression (Fig 8). 
 
 
Fig. 8. Effect of 15-d-PGJ2 on NF-B and impact on HIV-1 transcription. 
www.intechopen.com
 Emerging Roles of Prostaglandins in HIV-1 Transcription   
 
359 
4. Conclusion 
AIDS patients exhibit abnormal production of cyclooxygenase products. Prostaglandins 
are complex immunomodulatory molecules that shape, on one hand, the immune system 
and, on the other hand, have an influence on gene transcription by inducing or repressing 
several transcription factors in cells. Recent studies have led to a better understanding of 
the unique characteristics and importance of prostaglandins on HIV-1 transcription and 
replication (Fig 9). 
 
 
Fig. 9. A model for prostaglandins actions on HIV-1 pathogenesis. 
Because of their intrinsic intracellular obligatory parasitic form of life, viruses depend 
heavily on cell metabolic machinery for their replication. Thus, changes in cellular 
metabolism might influence the viral life cycle. The data reported in this chapter highlight 
the positive action of PGE2, a powerful cAMP-inducing agent, on the regulatory elements of 
HIV-1. PGE2 has now emerged as an immuno-activator that acts on the EP4 receptor that 
facilitates HIV-1 LTR activation. Elevated levels of PGE2 detected in HIV-1-infected persons 
or induced by opportunistic pathogens might actively participate to immunological 
disturbances associated with AIDS and modify the pathogenesis of this retroviral disease by 
inducing a higher viral load. High concentrations of PGE2 (up to 100 μM) found in seminal 
fluids of HIV-1-infected persons might directly enhance virus replication and facilitate viral 
transmission during sexual activities. Thus, analysis of the role of the PGE2 signaling may 
provide deeper insight into the pathological mechanisms underlying HIV/AIDS 
exacerbation, which should be fully taken into account in developing an EP4 antagonist as a 
therapeutic agent and its clinical application.  
Accumulating data from several studies suggest that PGJ2 has intracellular effects that may 
suppress inflammation. They include inhibition of NF-B by multiple mechanisms such as 
IB kinase inhibition, blockade of NF-B nuclear binding and activation of PPAR-. The 
consequences of these activities are complex, but are likely to play a role in the prevention 
and/or resolution of inflammation. In this chapter, we showed the potentiality of the anti-
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inflammatory molecule, PGJ2, to modulate the NaBut effect on HIV-1 LTR in intestinal 
epithelial cells by a PPAR-Ǆ-independent mechanism via the inhibition of NF-B 
translocation to the nucleus. These results suggest that such prostaglandins may have 
therapeutic value in the treatment of HIV-1 infected individuals where inhibition of NF-B 
activity may be required. 
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